Xencor, Inc. (XNCR)

Over the past six months, Xencor reported its Third Quarter 2025 Financial Results in November 2025, highlighting clinical data for XmAb819 and XmAb541, and the initiation of the Phase 2b XENITH-UC study for XmAb942. In December 2025, Xencor announced an extension of the U.S. patent term on certain Xtend™ Antibodies and participated in investor conferences. In January 2026, Xencor highlighted its corporate priorities and 2026 pipeline milestones. In February 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results and participated in investor conferences. In March 2026, Xencor announced a significant change to its Ultomiris® royalty revenue forecast, leading to a stock price drop and an update to its year-end cash guidance. The stock has experienced general volatility, with a 52-week range between $6.92 and $18.69.

As a clinical-stage biopharmaceutical company, Xencor's revenue is primarily derived from collaborations, licensing agreements, and milestone payments, and is not subject to typical seasonal fluctuations. The progress of its clinical trials, regulatory milestones, and the initiation or expansion of partnerships are the main drivers of its financial performance, which do not inherently follow seasonal patterns. Once its drug candidates are approved and commercialized, the demand for those therapies would be driven by medical need and disease prevalence, which are generally not seasonal for cancer and autoimmune conditions.

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, utilizing its proprietary XmAb® technology platform to create therapeutic candidates with enhanced properties. The company's pipeline includes over 20 clinical-stage candidates, developed internally and through collaborations. Key drug candidates include XmAb819 for advanced clear cell renal cell carcinoma, XmAb541 for advanced gynecologic and germ cell tumors, XmAb942 for inflammatory bowel disease, and Plamotamab for non-Hodgkin's lymphoma and rheumatoid arthritis. Xencor's technology is also incorporated into marketed products by partners, such as Ultomiris® and tafasitamab.

Xencor, Inc. is headquartered in Pasadena, California, with additional operations in San Diego, California. While its primary physical operations are in California, its impact is global. The company conducts clinical trials in multiple countries and engages in strategic partnerships and licensing agreements worldwide, extending the reach of its technology and drug candidates.

Xencor maintains a reputation as an innovative, science-driven biopharmaceutical company focused on engineering antibodies to treat serious diseases. Its XmAb® technology platform is well-regarded, leading to partnerships with major pharmaceutical companies. However, the dispute with Alexion Pharmaceuticals, Inc. regarding U.S. royalty payments for Ultomiris® could potentially affect its reputation. Despite this, the company emphasizes its commitment to translating innovative science into life-changing therapies.

Xencor's ownership is primarily distributed among institutional investors, mutual funds, and individual shareholders, including major holders like BlackRock, Inc., Primecap Management Co/ca/, and Vanguard Group Inc. The company's co-founders, Dr. Bassil Dahiyat and Dr. Stephen Mayo, also retain ownership stakes. Insider ownership contributes to the overall ownership structure.